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ABSTRACT 
Background: Coeliac disease (CD) occurs in approximately 1% of the Western population. It is a 46 
lifelong disorder associated with impaired life quality and an excess risk of comorbidity and death. 47 
Objectives: To review the literature on screening in CD in relation to the current WHO criteria for 48 
mass screening. 49 
Methods: We performed a PubMed search to identify papers on screening indexed in PubMed with 50 
a publication date 1900 until 1st of June 2014. When an abstract was deemed relevant, the 51 
corresponding paper was read in detail.  52 
Results: CD fulfils several WHO criteria for mass screening (high prevalence, available treatment, 53 
difficult clinical detection), but it has not yet been established that treatment of asymptomatic CD 54 
reduces the excess risk of severe complications, leads to higher life quality or is cost-effective. 55 
Conclusion: Current evidence is not sufficient to support mass screening for CD, but active case-56 
finding may be appropriate, recognizing that most patients with CD will still be missed by this 57 
strategy.  Although proof of benefit is still lacking, screening may be appropriate in high-risk 58 
groups. 59 
 60 
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 66 
Introduction 67 
Coeliac disease (CD) occurs in about 1% of the Western population.1, 2 A recent multinational study 68 
in Europe found big differences in CD prevalence with the lowest prevalence (0.3%) in Germany 69 
and the highest in Finland (2.4%) despite using common criteria for CD diagnosis.3  70 
The prevalence of CD seems to be increasing.4-7 A true increase in prevalence is probably one 71 
explanation, but other factors may also have contributed. Increased awareness of the complications 72 
of CD (including the mortality excess8), in combination with the advent of serological tests with 73 
high sensitivity and specificity9-12 mean that active case finding in CD has increased dramatically in 74 
the last decades. Among groups where screening is now becoming more and more common are 75 
first-degree relatives, and patients with type 1 diabetes13, 14.  76 
The main objective of this paper was to review the literature on screening for CD, in relation to the 77 
established criteria for mass screening established by the World Health Organization (WHO). 78 
 79 
 80 
 81 
 82 
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Methods 84 
This project was part of a wider effort, initiated by the British Society of Gastroenterology (BSG) 85 
and the Oslo group,15 to establish recommendations for the care of coeliac patients. JFL and DSS 86 
coordinated that overall effort. As part of a major review on clinical management of CD 14, we 87 
briefly described the role of screening for CD. In the current paper we expand that discussion, and 88 
look at the background of screening, and the pros and cons for CD screening, including the impact 89 
that such detection of CD will have on dietary adherence, outcome and quality of life. 90 
The working group for the present paper was made up by of seven authors from six different 91 
countries (Britain: n=2; and one author each from Sweden, Finland, Italy, Argentina and the US). 92 
Four authors (JFL, TC, KK and JAM) carried out the literature searches, the data collection and 93 
took the main responsibility for the writing of the paper. JB, FZ and DS provided important 94 
feedback, and contributed to crucial revising of the paper. All authors stand behind the paper. JFL 95 
wrote the first draft. 96 
The recommendations of this paper were based on a systematic literature review in PubMed for the 97 
time period 1900 until June 1, 2014 (search criteria have been listed in the appendix). Initially we 98 
carried out seven PubMed searches (Appendix) but given the large number of hits for three of these, 99 
we limited our literature review to the remaining four terms combined with British and American 100 
spelling of coeliac disease (search terms: “definition”, “cultural”, “diagnostic delay”, and 101 
“undiagnosed and (complication or comorbidity)”). The parts of this paper dealing with CD 102 
prevalence, treatment (gluten-free diet, GFD) and serological sensitivity/specificity were based on 103 
personal knowledge of the authors. Finally, CD screening in general was discussed within the 104 
author group. 105 
 106 
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Results 107 
WHO stipulates a number of criteria that need to be met to support mass screening (Table 1). While it is 108 
evident that CD readily meets many of these criteria, others have not yet been met. For example CD is more 109 
prevalent than some disorders for which there is already mass screening (e.g. phenylketonuria, PKU), but it 110 
is unclear whether early detection of CD has a positive societal impact. In contrast, detecting a child with 111 
PKU will allow prevention of devastating consequences for the development and life quality of that child. 112 
 113 
Prevalence of CD 114 
I) That the disease is common and well defined. In much of the western world, CD affects about 115 
1% of the population, but the prevalence varies between countries (e.g. 0.3% in Germany,3 0.7% in 116 
Italy,3 0.7-0.8% in the US,16, 17 and 1.8% in Sweden2). There are reports of even higher prevalence 117 
in certain calendar- and age-specific population-strata in Sweden18.  118 
The proportion of individuals with CD who have received a physician-assigned diagnosis of CD 119 
also varies (e.g. 25% in Finland and 6% in Italy)3 probably reflecting the general awareness of CD 120 
in each country. The ratio between diagnosed and undiagnosed CD has implications for screening 121 
since with a large proportion of undiagnosed CD, the arguments for screening become stronger. 122 
Despite slightly varying prevalences of CD, it is one of the most common lifelong diseases in any 123 
Western country (especially in children). While prevalences of CD may be lower in some non-124 
Western countries19, 20 there are also reports of extremely high prevalences in others21. We conclude 125 
that this WHO condition is fulfilled. 126 
 127 
There is currently an ongoing debate on how to define CD. Our research group recently published a 128 
paper on definitions of CD where CD was defined as “a chronic small intestinal immune-mediated 129 
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enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals”.15 130 
The related non-coeliac gluten sentivitity15, 22, 23 was defined as “one or more of a variety of 131 
immunological, morphological or symptomatic manifestations that are precipitated by the ingestion 132 
of gluten in people in whom CD has been excluded”.15 The definition of CD has important 133 
implications for CD screening since most research on complications and life-quality so far has been 134 
performed in individuals with biopsy-verified CD, and data cannot automatically be extrapolated to 135 
non-coeliac gluten sensitivity. The risk of complications may also vary with underlying 136 
histopathology in CD24. 137 
 138 
Serology – Sensitivity and specificity  139 
II) That screening tests are simple, safe and accurate. The WHO stipulates that for mass screening 140 
to be an option, screening tests with high sensitivity, specificity,25 positive predictive value (PPV) 141 
and negative predictive value (NPV) must be available. For any of the available tests a most 142 
important aspect is that the testing should be carried out when the patient is on a gluten-containing 143 
diet. It is therefore of crucial importance that the patient remains on a normal diet throughout the 144 
investigation for CD, and our discussion assumes this will be so. 145 
 146 
So-called antigliadin antibodies used in the 1980s and 1990s have low PPV even in high-risk 147 
groups; and have therefore largely been replaced by the more specific endomysium (EMA) and 148 
tissue transglutaminase antibodies (TTG). The introduction of endomysium antibodies was initially 149 
promising since their sensitivity and specificity seem to be at least 90-95%, but over time issues 150 
regarding interobserver reliance/interpretability, and cost, have limited its use as the first-line-151 
screening tool for CD. Though TTG antibodies can also be elevated in non-CD diseases, such as 152 
liver disease,26 gastrointestinal infections27 and certain heart diseases28, 29, TTG like EMA offers 153 
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high sensitivity and specificity30. One further test has recently gained some popularity. This is for 154 
deamidated gliadin peptide antibodies (DGP). One meta-analysis however found that TTG 155 
performs better than DGP.31 156 
 157 
TTG therefore is often used for screening of high-risk groups, but has also been used in large-scale 158 
screening projects of the general population including that of a multi-national European study 159 
encompassing more than 29,000 individuals.3 In the European multi-centre study, 75% 160 
(n=292/391) of individuals with positive TTG were positive for EMA but only 2.6% of those with 161 
borderline TTG values (n=10/384).3 In the 147 individuals with both positive EMA and 162 
positive/borderline TTG, 100 had an enteropathy typical of CD, equalling 68%.3 When Hopper et 163 
al screened a population of 2000 individuals undergoing endoscopy (for various indications) the 164 
PPV for CD (as defined by villous atrophy) in TTG+ individuals was 28-29%,32 but with a much 165 
higher figure reported in a general population study by Katz et al33 as well as by Sugai et al 34. 166 
Even a PPV of around 30% compares favourably with the PPV of e.g. guaiac faecal occult blood 167 
(FOB) testing for colorectal cancer (a test which has already been accepted for screening in a 168 
number of countries). As in the case of FOB screening however confirmatory testing is 169 
recommended (in the case of CD in adults, through small intestinal biopsy14).  170 
 171 
One further aspect to consider in the use of TTG is that when determining TTG (TG2 antibodies) by 172 
ELISA, it is important to bear in mind that the performance of the commercial ELISA TTG assays 173 
may vary depending on the quality of the TTG antigen 35. The method of extraction, the purity of 174 
TTG and the production and processing of recombinant antigen may all have an effect on test 175 
results35-37. Furthermore, as TTG can exist in two divergent conformations (open extended or 176 
closed) dependent on the activity of the enzyme,38 this also influences the performance of the assay, 177 
the open TTG being the superior antigen39. For the above-mentioned reasons the different 178 
commercial TTG-ELISA tests can yield differing numbers of false-negative or false-positive results. 179 
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Sequential strategies may also be used to increase the positive predictive value2, 40. 180 
When screening may be insufficient  181 
Under certain circumstances, a negative screening test cannot rule out CD. This will occur when the pre-test 182 
probability of CD is elevated. For instance, individuals with severe gastrointestinal symptoms, especially 183 
those with a family history of CD, should undergo small intestinal biopsy even in the absence of elevated 184 
antibodies41. Similar arguments apply to children with growth failure and individuals with severe 185 
gastrointestinal symptoms and at the same time another autoimmune disease such as type 1 diabetes, 186 
thyroid disease or Addison’s disease. Although, IgG-based serology tests have developed in recent years, a 187 
combination of IgA deficiency and gastrointestinal symptoms may also constitute an indication for biopsy. 188 
One way to effectively exclude CD in IgA deficient individuals is to perform an HLA-test first thereby 189 
ruling out CD in those negative for DQ2 or DQ8. Differential diagnoses such as common variable 190 
immunodeficiency (CVID) or and severe giardia should also be considered.  191 
 192 
Screening is culturally acceptable 193 
A third WHO criterion is that a screening test should be culturally acceptable. There are areas in the 194 
world,42 where blood testing may not be culturally but in the majority of countries (including those 195 
where earlier research has shown a high prevalence of CD), blood testing is culturally accepted. 196 
 197 
The GFD  198 
IV. That a treatment is available. This condition is clearly fulfilled in CD. GFD is an effective 199 
treatment for CD, and in symptomatic patients the benefits of the dietary treatment are well 200 
established, as it has been shown to decrease clinical symptoms as well as reduce the excess risk of 201 
complications. 43-45 202 
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 Nevertheless, the advantages of dietary treatment in screen-detected apparently asymptomatic 203 
individuals remain doubtful, and it is by no means settled that GFD results in similar health gains.46-204 
50 51 However, it is important to note that many screen-detected CD patients are not truly 205 
asymptomatic at diagnosis, and may once on a GFD recognize that they had suffered from CD-206 
related symptoms before the diagnosis. It is suggested that many undiagnosed coeliac patients 207 
accept a state of chronic vague ill health as a normal condition, but recognize this only after they 208 
have been placed on a GFD47, 52, 53 54. A recent randomized study also showed that apparently 209 
asymptomatic EMA positive subjects seem to benefit from their serological screening and 210 
subsequent GFD 55, thereby supporting earlier evidence from Dickey et al 56. Some authors have 211 
however suggested that EMA positivity in individuals with normal mucosa constitute a separate 212 
entity (potential CD), different from CD57. 213 
A strict GFD sets major limitations on daily life, it is expensive and difficult to maintain58, 59. 214 
Furthermore, removal of gluten from baked products makes them less palatable than comparable 215 
products in the normal diet. Due to these unpleasant aspects, the adherence with the GFD often 216 
remains inadequate60. Individuals found through screening programs to have CD may feel 217 
themselves healthy and they do not expect to gain health on treatment similar to those detected due 218 
to symptoms. Consequently, screen-detected subjects may be even less willing to adhere to a strict 219 
GFD.53, 61 62 The possible non-adherence to GFD is an essential issue when weighing the harms and 220 
benefits of CD screening, as a low rate of adherence would abolish any advantages of screening. It 221 
is important in this regard to recognise that good dietary adherence can be achieved in screen-222 
detected CD patients (adherence rates of 85% in symptom-detected CD patients and 79-91% in 223 
screen-detected ones),53, 63 even after long-term treatment52, 64. However, there is evidence to 224 
suggest that dietary lapses could be more common in the initially asymptomatic screen-detected 225 
patients than in the symptomatic ones53. Furthermore, patients suffering from type 1 diabetes 226 
mellitus and found to have CD by risk-group screening, may evince lower dietary adherence rates 227 
than reported in screening studies in general (40-63%)65-67.  228 
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When prescribing GFD to healthy screen-detected patient, one should remember that GFD is not 229 
nutritionally optimal and may have adverse consequences. GFD may potentially expose individuals 230 
to high sugar and low fibre and mineral intake68, 69, which again might cause different long-term 231 
negative health consequences such as constipation70. In addition, there is concern that patients 232 
might gain undesirable weight while on a GFD71, 72. Altogether, it would thus be essential to 233 
evaluate the consequences of GFD treatment before any screening programs for the disease are 234 
instituted. 235 
 236 
 237 
Diagnostic delay 238 
V. That clinical detection is difficult. Typically CD is characterized by diarrhoea, malabsorption and failure 239 
to thrive in childhood although during the last two decades the age of diagnosis has shifted upward and 240 
many patients have only minor symptoms.73-75 Due to the inconsistency of the symptoms, a substantial 241 
proportion of coeliac patients have a previous diagnosis of irritable bowel syndrome76 77. Unfortunately 242 
these symptoms do not predict CD in general population studies 2, 33, 78, 79. Furthermore, increasing numbers 243 
of CD patients are diagnosed because of extraintestinal symptoms or by screening of at-risk groups73, 74. 244 
Probably due to the vague nature of presenting symptoms, the delay from first symptoms to CD diagnosis 245 
has been reported to be unacceptably long, at between 5 and 10 years, for many persons73, 80-85, and the need 246 
for earlier diagnosis, even by mass screening has been advocated. 247 
 248 
 249 
 250 
 251 
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Untreated disease leads to complications 252 
VI. That if undiagnosed and untreated the disease will lead to severe complications. The WHO 253 
stipulates that prevention of complications shall follow upon disease detection if mass screening is 254 
implemented. This statement is conditional on two facts: 255 
a) That undiagnosed disease confers complications; and b) that these complications can be 256 
prevented by the “treatment”, in this case the GFD. Given the importance of genetic factors in the 257 
aetiology of CD, it may be assumed that comorbidity linked to underlying shared risk factors 258 
cannot be modified by diagnosing CD and introducing a GFD. 259 
It seems clear that the majority of gastrointestinal symptoms in CD are alleviated after the 260 
introduction of a GFD, but the evidence is less clear whether most complication are influenced by 261 
GFD. Weaknesses of previous research in this area include lack of strict evaluation of GFD, low 262 
study power, short follow-up, and a difficulty in disentangling the effects of age at diagnosis, and 263 
duration of gluten exposure, which will both be linked to early diagnosis.  264 
It should be noted that duration of disease is not equal to diagnostic delay. In the recent Proconsul 265 
study, complications in CD were associated with a short diagnostic delay86, but it cannot be ruled 266 
out that earlier celiac diagnosis was prompted by symptoms and signs from the celiac complication. 267 
 268 
Morbidity and mortality in undiagnosed CD  269 
Mortality 270 
A number of studies have examined mortality in undiagnosed CD6, 51, 87-90. Two of these have 271 
shown excess mortality6, 90. Of particular interest is the study by Rubio-Tapia, which is the only 272 
study with extensive follow-up duration6. That study found an almost 4-fold increased risk of death 273 
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in young men with positive CD serology, but confidence intervals were wide (95%CI=2.0-7.5), the 274 
number of participants with CD low (n=14) and the population studied was restricted (military 275 
recruits) so results may not be generalizable. It is also not clear, how many of these individuals 276 
would have been diagnosed applying modern aggressive case-finding for CD91 as many individuals 277 
diagnosed in screening studies have a history of CD-associated symptoms.47 Other larger-scale 278 
studies have shown no increased risk of death in undiagnosed CD (numbers of screened adults: 279 
16,847;89 7,527;87 and 6,98788). 280 
 281 
Autoimmunity 282 
Studies on undiagnosed CD and autoimmune disease are difficult to carry out since patients with 283 
autoimmune disease are often screened for CD, and because the onset of autoimmune disease is 284 
often gradual (in contrast to mortality, but also to some extent to malignancy). As far as we know, 285 
none of the studies looking at undiagnosed CD and mortality have looked at development of 286 
autoimmune disease.6, 51, 87-90 287 
 288 
Cosnes et al investigated 924 patients with CD. While they concluded that the GFD had a 289 
protective effect against autoimmunity, this effect was weak since it did not remain statistically 290 
significant when the authors adjusted for other co-variates in their multivariate analyses (p=0.07).92 291 
The Cosnes et al study also found that a late diagnosis of CD decreased the risk of autoimmune 292 
disease.92 Finally, two Italian studies have suggested that GFD may decrease the prevalence of 293 
thyroid autoantibodies93, 94, but whether it protects against hypo- or hyperthyroidism is still unclear.  294 
 295 
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We may however want to consider the effect of a GFD not only upon the cumulative incidence of 296 
autoimmune disease in those with CD but also upon the control of disease in individuals who 297 
already have an autoimmune disease (other than CD). Diagnostic delay of CD is common in type 1 298 
diabetes95 and the longterm consequences of this are unknown. Recent Swedish data however 299 
indicate that long term CD is associated with excess morbidity in type 1 diabetes96-98. Hansen et al 300 
screened children with type 1 diabetes, but did not see an improvement of HbA1C in diabetes 301 
patients who were detected with CD and then recommended a GFD.99 A British study of adults with 302 
type 1 diabetes however found that patients with undiagnosed CD had worse HbA1C (8.2) than 303 
controls (7.5)(p=0.05) at baseline, but when after 1 year the authors compared HbA1C values, there 304 
was no difference between those adhering to a GFD and those with poor adherence.100  305 
 306 
Malignancy 307 
A recent meta-analysis even suggested that the overall malignancy risk in diagnosed CD was not 308 
elevated compared to that of general population-based controls,101 but individual cancers, such as 309 
lymphoproliferative cancer and gastrointestinal cancers,102, 103 may still be positively associated 310 
with CD. One reason for a seemingly neutral association between diagnosed CD and risk of overall 311 
cancer (or a very limited risk increase) is that high relative risks for less common cancers 312 
(lymphomas) may be compensated for by lower relative risks for common cancers such as breast 313 
cancer.104, 105  314 
We know of three studies so far exploring cancer risk in undiagnosed CD, none of which found any 315 
increase in overall cancer but study power was limited.89, 106, 107 In addition to these there are at least 316 
another two case control studies specifically of lymphoma, which have shown an excess risk in CD. 317 
Catassi et al108 found a 3.1-fold excess of Non Hodgkin Lymphoma among Italian individuals with 318 
undiagnosed CD and 16.9 for gut lymphoma. The latter of these figures closely mirrors the odds 319 
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ratio of 15.7 for the occurrence of gut lymphoma in undetected CD from Johnston and Watson in 320 
Northern Ireland109. As with mortality however one must consider the risk in those with diagnosed 321 
disease. Since the risk of NHL remains greater in diagnosed disease at about 4 to 6 fold24, 103, 110 (and 322 
that of small bowel lymphoma (SBL) may be even higher in this group111) , again a substantial 323 
societal benefit in the reduction of cancer occurrence or death from mass screening for celiac 324 
disease seems unlikely.  325 
 326 
Considering that the overall risk of malignancy in CD does not seem to be increased more than 327 
marginally,101 most interest with regards to the potentially protective effect of GFD focuses on 328 
lymphoproliferative malignancy. That earlier research on undiagnosed CD has failed to show an 329 
association with malignancy, including lymphoproliferative malignancy argues against GFD 330 
playing a major role. At the same time, it should be noted that most earlier studies have been 331 
underpowered to examine the relationship between GFD and lymphoproliferative malignancy 332 
(number of CD patients with lymphoma or non-Hodgkin lymphoma: 9,112 9,44 and 9103). In an effort 333 
to examine the role of GFD, Olén et al reviewed patient charts (the researchers were blinded to CD 334 
status) of 59 patients with both CD and lymphoma, as well as 137 CD patients without lymphoma. 335 
This nested case-control study was still underpowered to confirm a suspected relationship between 336 
poor dietary compliance and future lymphoma (OR=1.83; 95%CI=0.78-4.31).113  337 
Current data implies that there is a protective effect of GFD against lymphoma, although that has 338 
not yet been comprehensively proven. 339 
 340 
 341 
 342 
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Pregnancy and fertility 343 
Adverse pregnancy outcome in maternal undiagnosed CD has now been confirmed by a number of 344 
studies, 114-116 including two recent papers that both found increased risk estimates for preterm birth 345 
in undiagnosed CD (Sweden: 1.71117; Denmark: 1.33116), but not in diagnosed CD. This association 346 
strongly argues that a CD diagnosis and a GFD introduced before pregnancy influence the 347 
pregnancy outcome. As both studies were of clinically diagnosed cases, they do not however 348 
clearly demonstrate a benefit to screening for asymptomatic ones. 349 
 350 
That undiagnosed CD has a negative effect on birth outcome cannot automatically be translated into 351 
an effect on fertility. The largest screening study for CD in subfertile/infertile couples so far found 352 
no association with CD118, and the two largest cohort studies to this date119, 120 have found that 353 
overall fertility in CD is similar to the of general population controls, even though the Swedish 354 
study found a fertility decrease in the last two years before diagnosis followed by catch up 355 
fecundity after diagnosis119. It cannot be ruled out that the decrease in fertility just before diagnosis 356 
seen in that paper is due to undiagnosed CD,119 but it might also be due to other comorbidity which 357 
lead to testing for CD, or that women postpone pregnancy when they undergo extensive medical 358 
investigations.  359 
 360 
Advantages of undiagnosed CD?  361 
Although we do not argue that patients with symptomatic CD should remain undiagnosed, several 362 
papers suggest that the prevalence of hypertension,121 hypercholesterolemia121, 122 and obesity123 is 363 
lower in undiagnosed CD than in the general population,121 potentially protecting against 364 
cardiovascular disease. In fact, some authors have argued that screen-detected children without 365 
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symptoms should not always be treated with GFD.52 The largest study on diagnosed CD and 366 
cardiovascular disease however found a small but statistically significant increased relative risk for 367 
both incident ischemic heart disease and death from ischemic heart disease.124 Such a risk increase 368 
does however translate in a substantial absolute risk considering that cardiovascular disease is 369 
common (in celiac individuals aged 60+ years, the excess risk was 20 myocardial infarctions per 370 
1000 person-years124). 371 
 372 
Life quality aspects of screening of CD 373 
In symptomatic CD the GFD results in rapid recovery from symptoms paralleled with improvement 374 
in quality of life53 125 46, 126, 127 (Table 2). However, screen-detected CD patients may have considered 375 
themselves healthy before the diagnosis, and now the stigma of a chronic disorder128 and need of 376 
major dietary restrictions may potentially even increase their self-perceived burden of illness and 377 
impair their quality of life129-131.  378 
 379 
Prospective studies on quality of life in CD patients detected by screening of at-risk groups or in 380 
populations in general are limited (Table 2). According to these studies quality of life in screen-381 
detected coeliac patients at or before diagnosis, especially in those who are asymptomatic, is often 382 
similar to,46, 53, 126 50, 125 or lower 47, 52, 53 than that found in control populations. In screen-detected 383 
patients, GFD treatment does not necessarily result in improvement of life-quality46, 53, 126 but some 384 
studies imply that the diet may have a positive impact in health and well-being in these patients also 385 
47, 52, 53 125. Still, data suggest that screen-detected patients without symptoms may experience the 386 
diagnosis of CD more negatively than patients having symptoms48, 53. This would suggest that early 387 
detection of CD by mass screening in a healthy adult population would not unequivocally result in 388 
self-perceived health gain. Furthermore, data on long-term treatment in screen-detected patients is 389 
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scarce52, 64. These issues call for comprehensive studies before implementation of large-scale CD 390 
screening programs. 391 
 392 
Cost-benefit of screening  393 
VII. That testing and treatment is cost-effective. As has been outlined above the likely benefit or 394 
even the potential harm to undetected coeliac patients from screen detection is as yet poorly 395 
defined. In addition symptomatic undiagnosed CD and diagnosed CD are both likely to confer 396 
increased costs to the individual patient and to society, but these costs are shared differently in 397 
different countries. Determining whether screening and detection of asymptomatic CD will lead to 398 
health gains at an acceptable cost or even to economic benefits is therefore extremely difficult. A 399 
number of studies have however been conducted in this area. Some of these consider only the costs 400 
of detecting a new case by varying screening strategies, or apply only to specific high risk groups, 401 
and there are very few which have attempted to model both costs and health benefits to determine 402 
the cost of gaining a quality adjusted life year (QALY), and only three of these refer to general 403 
population screening. In a UK context perhaps the most influential of these papers to date has been 404 
the HTA (Health Technology Assessment) sponsored study by Dretzke et al132 (the only such study 405 
considered in the development of the current UK national guidelines, and one specifically looking 406 
at newly diagnosed type I diabetic children). This study found that serological testing followed by 407 
confirmatory biopsy and treatment with GFD provided additional QALYs at an incremental cost of 408 
between £12,250 and £20,160 when performed in children with newly diagnosed type 1 diabetes. 409 
To derive these estimates the authors assumed among other things that untreated asymptomatic CD 410 
would cause the loss of 4 years of life, and reduce quality of life from 88% of optimal (the assumed 411 
baseline for treated disease) to 82% of optimal. Another prominent analysis by Hershcovici et al 412 
has examined the cost effectiveness of mass screening. This paper found that the cost for each 413 
QALY gained through mass CD screening is about 49,000 USDs (Table 3).133 However, it is 414 
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important to note that this cost, and the conclusion that mass screening in young adults is cost-415 
effective is again based on a number of assumptions. The authors of the Hershcovici et al paper 416 
assumed that the standardized mortality ratio was 1.6 in patients with symptoms (“undiagnosed”), 417 
and 1.1 in patients on a GFD (“diagnosed”).133 However, most studies on mortality in diagnosed 418 
CD have found relative risks of deaths of around 1.3-1.4 8, 104 (and in a Swedish study,8 it was 419 
estimated that 83% of patients adhered to the diet). Hence, with a smaller gap between the mortality 420 
risk estimates between diagnosed and undiagnosed coeliac patients, mass screening may not be 421 
cost-effective. This is well illustrated by the study by Shamir et al (Table 3)134, which though 422 
finding on an assumption of an SMR of 1.6 for undetected disease, screening to be cost effective, 423 
showed in a sensitivity analysis that if the SMR fell to 1.3 then the cost per QALY rose to over 424 
$100,000. Cost-effectiveness analyses are also dependent on degree of adherence to a GFD, and 425 
where Hershcovici et al assumed a dietary adherence of 80% in patients with symptomatic CD, 133 426 
others have found the lowest dietary adherence in screen detected asymptomatic patients .49 Finally, 427 
cost-effectiveness is dependent on duration of symptoms before diagnosis. Hershcovici et al 428 
reported that mass screening would be effective if diagnostic delay was 6 years of more. With 429 
increased awareness of CD, diagnostic delay is likely to decrease. At present, some studies suggest 430 
that the delay is ≥6 years80, 85 but others that it is less (4.9 years135). Finally Park et al136 recently 431 
compared two different strategies to prevent bone loss and fractures in patients with undiagnosed or 432 
subclinical CD. Their study found that symptomatic at-risk screening was more cost-effective than 433 
universal serological screening. Though again the assumptions of their base model can be 434 
challenged, they found that screening of symptomatic and high risk subjects was a dominant 435 
strategy when compared to universal screening producing greater QOL gains at lower cost. 436 
Furthermore this strategy remained the more cost effective option when testing the sensitivity of the 437 
model to variation in their assumptions. 438 
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We conclude that more data on the cost-effectiveness of mass screening for CD in the general 439 
population is needed.  440 
 441 
When and how often should we screen? 442 
It should be clear to all that for so common a disease as CD, and with so successful a therapy as 443 
GFD, any patient with symptoms that might be due to CD should be tested. In this paper however 444 
we are primarily concerned with the asymptomatic. For them as should be clear from the forgoing 445 
we cannot point to definite benefit from the detection of CD (either in the reduction of symptoms – 446 
since they have by definition none, or an increase in the quality or the quantity of life). 447 
Furthermore, unlike in congenital diseases such as congenital hypothyroidism where screening once 448 
is enough to rule out disease, CD can start at any age, and having a negative CD serology test does 449 
not rule out future CD.  450 
With regard to the second of these issues, there is at least one CD screening method with an 451 
exceptionally high negative predictive value: HLA-screening. Patients with a negative HLA will 452 
not develop CD and one strategy to avoid repeated CD screening is to first perform an HLA test. 453 
One drawback of HLA screening is its extremely low positive predictive value (PPV)(1 in 25 DQ2-454 
DQ8 individuals will develop CD, i.e. the PPV is around 4%), while giving the patient and his/her 455 
physician the impression that the patient is “positive for CD”. 456 
No simple work around exists however for the lack of clear evidence of the benefit of screen 457 
detection. It is not unreasonable to assume however that there is a marginal benefit of such 458 
detection (as has been assumed in the cost efficacy studies of screening previously discussed), and 459 
any such benefit is likely to be greatest in high-risk groups where the PPV of a positive screening 460 
test will be greatest. On this basis therefore it is generally assumed that the screening of high-risk 461 
groups is reasonable, but direct evidence for this is lacking at present in almost all cases. 462 
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 463 
Special circumstances – High risk groups  464 
First-degree relatives 465 
The prevalence of CD in first-degree relatives is around 10%,16, 137, 138 with significantly higher 466 
prevalence figures in monozygotic twins, families with multiple affected or siblings who share the 467 
HLA susceptibility alleles.139  468 
 469 
Type 1 diabetes 470 
Up to one in three DQ2+ individuals with type 1 diabetes expresses TTG.140 Type 1 diabetes is also 471 
one of the most common autoimmune diseases in patients with CD, 92 and the relative risk for 472 
future type 1 diabetes in patients with CD has been estimated at 2.4.141 Of note, that relative risk is 473 
almost identical to the future risk of type 1 diabetes in whites who are DQ2,142 suggesting that the 474 
increased risk of type 1 diabetes may not be affected by dietary adherence.  475 
Between 2% and 12% of all type 1 diabetes patients have CD.16, 99, 143, 144 476 
 477 
Down syndrome and Turner syndrome 478 
Although, most studies so far have been small, the prevalence of CD seems to be increased in both 479 
Down syndrome148-150 and Turner syndrome151, 152. The only direct analysis of screening cost 480 
effectiveness in either of these conditions of which we are aware is the one by Swigonski et al.153 481 
This study though it focuses on the prevention of lymphoma, does also address the total number of 482 
QALYs resulting from a screening strategy in this group. It is notable in suggesting that screening 483 
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causes a reduction in QUALYs, and though this is based on the assumption that having to eat a 484 
GFD represents a 1% reduction in QOL, that assumption is perhaps no more unreasonable than any 485 
of those considered in the analyses of general population screening above. 486 
 487 
Iron-deficiency anaemia 488 
CD may cause iron-deficiency anaemia through malabsorption, but also through an ongoing 489 
inflammation and potentially also through occult bleeding145 146. CD is also more common in 490 
patients with iron-deficiency anaemia and gastrointestinal symptoms including IBS147, and we 491 
suggest that both these risk groups undergo testing.  492 
 493 
 494 
Bone mineralization disorders / Osteoporosis and osteomalacia  495 
CD is associated with an increased risk of fractures,154-156 with relative risks of around 2 for 496 
fractures after CD diagnosis. An earlier study found a similar relationship (Odds ratio around 2) for 497 
fractures prior to diagnosis in patients with CD.156 498 
499 
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Discussion and Recommendations  500 
There is an ethical difference between aggressive case-finding among the symptomatic, and 501 
screening for disease in the general population where a diagnosis of CD in asymptomatic 502 
individuals may not confer clear benefits. Decisions on screening therefore should be carefully 503 
considered. In this paper we have tried to review the pros and cons of mass screening for CD 504 
against the established WHO criteria for mass screening, and a summary of key-points in relation to 505 
screening is given in Table 4. Though CD meets many of these criteria, the outcome of undetected 506 
asymptomatic disease, the effect upon the life expectancy and quality of life with GFD in these 507 
patients and therefore the cost efficacy of screening remains unclear. Screen-detected CD will have 508 
economic implications, leading to both higher and lower costs, for different actors, and whether 509 
mass-screening is economically sound is dependent on a number of assumptions. Though studies to 510 
date assuming that GFD improves quantity and quality of life in the asymptomatic, and is itself cost 511 
free, suggest that screening may be cost effective, to achieve certainty we need more data to reduce 512 
the number of such assumptions which must be made.  513 
Neither the current NICE guidelines157 on recognition and assessment of CD, nor the corresponding 514 
British Society of Gastroenterology (BSG) guidelines14 recommend mass screening for CD in the 515 
UK. Both guidelines do however recommend that serological testing for CD should be conducted in 516 
a wide range of clinical situations ranging from, the presence of potential symptoms of the disease 517 
(diarrhoea, failure to thrive (in children), gastrointestinal symptoms, prolonged fatigue, sudden or 518 
unexpected weight loss and anaemia), through the presence of associated conditions (autoimmune 519 
thyroid disease, dermatitis herpetiformis, irritable bowel syndrome or type 1 diabetes) to the 520 
presence of CD in a first degree relative. 521 
 522 
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Based on our literature review we suggest that screening of high risk groups may well be cost 523 
effective even if the benefit gained is small, however proof of such benefit is still lacking.  524 
We recommend that future research should provide data on the outcomes of undiagnosed and of 525 
treated asymptomatic CD.  526 
 527 
In conclusion, we cannot recommend mass screening at the present stage. Though current 528 
diagnostic recommendations will only lead to the discovery of a minority of patients with CD, it is 529 
not yet clear that the detection of more would be of benefit to those detected.  530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
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Table 1. Summary of WHO criteria 953 
WHO Criteria Valid 
in 
Coeliac 
disease 
Comment 
That the disease is common 
and well defined 
++ There is an agreement that the disease occurs in 
about 1% or more of the Western population. 
Disease criteria have however been debated. 
Screening tests are simple, 
safe and accurate 
++ Screening tests with tissue transglutaminase have 
high sensitivity and specificity but the positive 
predictive value is well below 100%. However 
when combined with sequential endomysial 
antibody testing the positive predictive value 
increases.  
The screening test should be 
culturally acceptable 
+++ Only very rarely is screening not culturally 
accepted 
Treatment is available +++ A GFD is beneficial for both symptoms and 
mucosal injury, but may not protect against many 
future complications of CD 
Clinical detection is difficult +++ Symptoms and signs vary. Some individuals with 
CD are asymptomatic. Most people with CD 
remain undetected.  
If undiagnosed and 
untreated the disease will 
lead to severe complications 
+ Symptomatic patients will most often be relieved 
of symptoms. It is less clear if asymptomatic 
patients will benefit from clinical diagnosis and 
treatment with a GFD. It is not known if 
asymptomatic individuals are at risk of severe 
complications. 
Testing and treatment is 
cost-effective 
+ There is little research in this field, and existing 
research has often been based on the assumption 
that CD goes undiagnosed for many years. With 
increasing awareness of CD, diagnostic delay is 
likely to have decreased in recent years.  
CD, coeliac disease. GFD, Gluten-free diet 954 
 955 
 956 
 957 
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Table 2. Quality of life (QoL) studies in screen-detected coeliac patients 959 
 960 
Reference Country Study 
design 
No of 
screen-
detected 
patients 
(asympto
matic) 
QoL 
instrument 
Main finding 
Mustalahti 
2002 125 
Finland Prospective 19 (14) PGWB At diagnosis QoL similar 
to that in controls; QoL 
improved significantly 
after 1-year’s GFD 
Johnston 
2004 46 
UK Prospective
* 
14 (ND) SF-36 At diagnosis QoL similar 
to that in controls; no 
change after 1-year’s 
GFD 
Viljamaa 
2005 64 
Finland Cross-
sectional 
53 (32) PGWB, SF-
36 
After long-term GFD, 
QoL was comparable to 
controls 
Korponay-
Szabo 
2007 47 § 
Hungary Prospective
* 
32 (5) Generic 
child health 
questionnair
e 
Global general health, 
bodily pain, general 
health perceptions, 
parental emotional 
impact lower than in 
controls; QoL improved 
after 1-year’s GFD 
Whitaker 
2009 48 
UK Cross-
sectional 
51 (19) Self-made 
questionnair
e 
A quarter of the 
asymptomatic screen-
detected patients 
regretted being 
diagnosed 
Van 
Koppen 
2009 52 § 
Netherlands Prospective
* 
32 (20) TNO-AZL# 
DUX 25#, 
CDDUX# 
Social functioning, 
problem behavior, 
anxiety, positive mood, 
liveliness affected in 
cases vs. control 
population. Improvement 
on GFD  
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Nachman 
2009 126 
Argentina Prospective (8) SF-36 At diagnosis QoL similar 
to that in controls; no 
change after 3 month’s 
GFD 
Ukkola 
2011 53 
Finland Prospective 146 (23) PGWB In all group, at diagnosis 
QoL was lower than that 
in controls; QoL 
improved after 1-year’s 
GFD. In asymptomatic 
group QoL similar to that 
in controls at diagnosis; 
no change after 1-year’s 
GFD 
Nordyke 
2011 50 § 
Sweden Cross-
sectional* 
148 EQ-5D Before diagnosis QoL in 
screen-detected CD 
similar to controls 
Nordyke 
2013 158 § 
 
Sweden Prospective 103 EQ-5D Screen-detected cases 
with unrecognized CD 
experienced similar QoL 
at diagnosis. On diet 
boys reported less pain 
Myleus 
2014 159 § 
Sweden Cross-
sectional 
238 Kidscreen Comparable HRQoL as 
their peers 
Kurppa 
2014 55 
Finland Randomized
, prospective 
40 PGWB 
SF36, VAS 
Anxiety alleviated and 
perception of health 
improved in favor of 
GFD, but 
social functioning 
reduced in favour of 
gluten consumption 
PGWB=Psychological General Well Being , GFD=Gluten free diet, SF-36=Short For-36. ND=No 961 
data. 962 
# Quality of life scales. For an explanation, see the original paper by Van Koppen 52 963 
*Detected by mass-screening; other studies include patients detected by risk-group screening 964 
§ Study based on children and/or adolescents. All other studies were based on adults. 965 
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Table 3. Cost effectiveness of mass screening for coeliac disease. 968 
 Shamir et al 134 Hershcovici et al 133 
Utility of life with untreated 
asymptomatic CD 
100% Irritable bowel syndrome 
76% 
Iron deficiency anemia 73% 
All other presentation 100% 
Utility of life on GFD 100% 98% 
SMR for untreated 
asymptomatic CD 
1.6 All assumed symptomatic. 
With SMR 1.6 
SMR in GFD 1.1 1.1 
Sensitivity of screening 85% IgA TTG 95% 
IgG TTG 98.7% 
Prevalence of CD 0.5% 0.9% 
Specificity of screening 90% TTG 
95% EMA 
IgA TTG 98% 
IgG TTG 98.6% 
Costs of screening from 2004 Medicare fees 2004 Medicare fees 
Cost of GFD Not considered Not considered 
EMA, Endomysial antibodies 969 
GFD, Gluten free diet 970 
SMR, Standardized Mortality Ratio 971 
TTG, Tissue transglutaminase antibodies 972 
 973 
 974 
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 978 
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Table 4. Key-points: Screening for CD 985 
Coeliac disease occurs in about 1-2% of the Western population 
The varied presentation makes the disease difficult to diagnose, and there are screening tools 
available 
There are still few data on complications from undiagnosed CD 
We recommend active case-finding, but not mass screening 
 986 
 987 
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 990 
 991 
 992 
 993 
 994 
 995 
 996 
 997 
 998 
 999 
 1000 
 1001 
Ludvigsson et al. 
 43 
 1002 
Appendix 1003 
 1004 
PubMed search Jan 1, 1900 until June 1, 2014. Number of hits searching for “(Coeliac or 1005 
coeliac)” and the below terms. 1006 
Additional term Hits 
+ Prevalence* 3612 
+ Definition 101 
+Cultural 353 
+Treatment or gluten* 141912 
+Sensitivity and specificity* 1376 
+Diagnostic delay 157 
+undiagnosed and (complications or 
comorbidity)# 
123 
E.g. PubMed search: 1007 
* Abstracts and/or titles not examined in detail. 1008 
Example of search strategy: ((coeliac or coeliac) and undiagnosed and (complications or 1009 
comorbidity)) AND ("1900/01/01"[Date - Entrez] : "2014/06/01"[Date - Entrez]) 1010 
 1011 
 1012 
 1013 
